{"id":37093,"date":"2025-07-10T15:43:04","date_gmt":"2025-07-10T07:43:04","guid":{"rendered":"https:\/\/flcube.com\/?p=37093"},"modified":"2025-07-10T15:43:05","modified_gmt":"2025-07-10T07:43:05","slug":"cstone-pharmaceuticals-receives-nmpa-approval-for-local-production-of-gavreto-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37093","title":{"rendered":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China"},"content":{"rendered":"\n

China-based CStone Pharmaceuticals (HKG: 2616<\/a>) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.<\/p>\n\n\n\n

Approval Details<\/strong>
The NMPA’s approval for local manufacturing represents a significant step forward for CStone Pharmaceuticals in expanding its capabilities within the Chinese market. By producing Gavreto domestically, the company aims to streamline its supply chain and ensure consistent availability of this critical therapy for patients with RET-related cancers.<\/p>\n\n\n\n

Gavreto Overview<\/strong>
Gavreto is an oral, once-daily, highly selective RET inhibitor that was in-licensed from US-based biotech Blueprint Medicines in June 2018. The drug has been approved for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer in multiple markets, including mainland China, Hong Kong, Taiwan, and the United States.<\/p>\n\n\n\n

Commercialization Partnership<\/strong>
In November 2023, CStone Pharmaceuticals partnered with Allist Pharmaceuticals Co., Ltd. for the commercialization of Gavreto in China. This collaboration is designed to maximize the drug’s market reach and ensure that patients have access to this innovative therapy.<\/p>\n\n\n\n

Significance of Local Manufacturing<\/strong>
The shift to local production underscores CStone Pharmaceuticals’ commitment to strengthening its presence in the Chinese market while addressing potential supply chain challenges. By manufacturing Gavreto domestically, the company aims to enhance its ability to meet patient demand and support broader healthcare initiatives in China.<\/p>\n\n\n\n

Conclusion<\/strong>
CStone Pharmaceuticals’ NMPA approval for local manufacturing of Gavreto marks a pivotal moment in its journey to expand access to life-saving therapies in China. As domestic production begins next year, the company is poised to play a key role in improving patient outcomes and solidifying its position as a leader in oncology innovation.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National…<\/p>\n","protected":false},"author":1,"featured_media":37094,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[138,2659,16,188,856,15],"class_list":["post-37093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-allist-pharmaceuticals","tag-blueprint-medicines","tag-cancer","tag-cstone-pharmaceuticals","tag-hkg-2616","tag-product-approvals"],"yoast_head":"\nCStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China\" \/>\n<meta property=\"og:description\" content=\"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T07:43:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T07:43:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China\",\"datePublished\":\"2025-07-10T07:43:04+00:00\",\"dateModified\":\"2025-07-10T07:43:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1011.webp\",\"keywords\":[\"Allist Pharmaceuticals\",\"Blueprint Medicines\",\"Cancer\",\"CStone Pharmaceuticals\",\"HKG: 2616\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37093#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37093\",\"name\":\"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1011.webp\",\"datePublished\":\"2025-07-10T07:43:04+00:00\",\"dateModified\":\"2025-07-10T07:43:05+00:00\",\"description\":\"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37093\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1011.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1011.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China - Insight, China's Pharmaceutical Industry","description":"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37093","og_locale":"en_US","og_type":"article","og_title":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China","og_description":"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.","og_url":"https:\/\/flcube.com\/?p=37093","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-10T07:43:04+00:00","article_modified_time":"2025-07-10T07:43:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China","datePublished":"2025-07-10T07:43:04+00:00","dateModified":"2025-07-10T07:43:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37093"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","keywords":["Allist Pharmaceuticals","Blueprint Medicines","Cancer","CStone Pharmaceuticals","HKG: 2616","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37093#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37093","url":"https:\/\/flcube.com\/?p=37093","name":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37093#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","datePublished":"2025-07-10T07:43:04+00:00","dateModified":"2025-07-10T07:43:05+00:00","description":"China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg) instead of importing the drug from overseas. This milestone is expected to enhance supply flexibility and improve patient access in China, with domestic production set to commence next year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37093"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37093#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","width":1080,"height":608,"caption":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1011.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37093\/revisions"}],"predecessor-version":[{"id":37095,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37093\/revisions\/37095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37094"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}